Milfasartan is an inhibitor of angiotensin II receptor type 1 was used in phase II clinical trial for the treatment of hypertension. However, these studies were discontinued.

Zolasartan (previously known as GR 117289) is an angiotensin II (AT1) receptor antagonist that was studied for the treatment of hypertension. It was undergoing phase II clinical trials with Glaxo Wellcome in the United Kingdom before the study was discontinued.

Forasartan (also known as SC-52458) was developed as an orally active, competitive angiotensin (Ang) II subtype 1 (AT1)-receptor antagonist for the treatment of hypertension. Forasartan competes with angiotensin II for binding at the AT1 receptor subtype. It is known that angiotensin II is a vasoconstrictor and stimulates the synthesis and release of aldosterone, and blockage of its effects results in a decrease in systemic vascular resistance. Information about the further development of forasartan is not available.

Embusartan or BAY106734 (6-n-butyl-4-methoxycarbonyl-2-oxo-1[(2'-(1H-tetrazol-5-yl) -3-fluorobiphenyl-4-yl)methyl] 1,2-dihydropyridine) is an angiotensin II receptors antagonist. Embusartan has beneficial effects in different animal hypertension models. Embusartan appears as a potent and specific new inhibitor of angiotensin II-induced growth-related events in vascular smooth muscle cells. It was being developed for the treatment of hypertension.

Elisartan (HN 65021) is a selective, orally active, nonpeptide angiotensin II (AT1) antagonist. It antagonizes angiotensin receptor-mediated vasoconstriction. Elisartan was being assessed for the treatment of hypertension.

Ripisartan (UP-269-6) is a specific nonpeptide angiotensin II receptor antagonist. Oral administration of ripisartan in rats and dogs resulted in a dose-dependent and long-lasting inhibition of the angiotensin II-induced pressor response. It did not show agonistic properties in animals. In vitro, ripisartan was found to bind selectively to AT1 receptors. In humans, it showed high biliary excretion and reabsorption. Canine studies have suggested it might have cardioprotective properties after acute ischemia-reperfusion.